Gregory Fraser's Stock Ratings

Truist Securities Analyst

Gregory Fraser is an analyst at Truist Securities. Analyst ratings are quantitative and qualitative analysis of a stock by Wall Street stock rating analysts. Stock ratings consist of expected future growth, current stock valuation and macroeconomic trends. Updated 05/17/2024

Overall Average Return

21.2%

Smart Score

Overall Average Return Percentile

80th

Number of Ratings

		Buy Now							Get Alert
04/30/2024	XAIR	Buy Now	Beyond Air	$1.39	475.54%	$10 → $8	Maintains	Buy	Get Alert
03/01/2024	ANIP	Buy Now	ANI Pharmaceuticals	$61.73	29.6%	$72 → $80	Maintains	Buy	Get Alert
02/16/2024	ANIP	Buy Now	ANI Pharmaceuticals	$61.73	16.64%	$70 → $72	Maintains	Buy	Get Alert
Make more informed trades with Benzinga Pro You're only getting a peek at the whole story!
01/18/2024	BTMD	Buy Now	Biote	$5.20	73.08%	$10 → $9	Maintains	Buy	Get Alert
11/14/2023	XAIR	Buy Now	Beyond Air	$1.39	619.42%	$14 → $10	Maintains	Buy	Get Alert
11/08/2023	AMRX	Buy Now	Amneal Pharmaceuticals	$6.82	2.64%	$6 → $7	Maintains	Buy	Get Alert
09/06/2023	AMRX	Buy Now	Amneal Pharmaceuticals	$6.82	-12.02%	→ $6	Reiterates	Buy → Buy	Get Alert
08/21/2023	ANIP	Buy Now	ANI Pharmaceuticals	$61.73	13.4%	→ $70	Reiterates	Buy → Buy	Get Alert
08/07/2023	AMRX	Buy Now	Amneal Pharmaceuticals	$6.82	-12.02%	$4 → $6	Maintains	Buy	Get Alert
08/03/2023	CORT	Buy Now	Corcept Therapeutics	$29.47	-1.58%	$26 → $29	Maintains	Hold	Get Alert
07/21/2023	XAIR	Buy Now	Beyond Air	$1.39	907.19%	$18 → $14	Maintains	Buy	Get Alert
07/21/2023	ANIP	Buy Now	ANI Pharmaceuticals	$61.73	-2.8%	$52 → $60	Maintains	Buy	Get Alert
06/06/2023	NVCR	Buy Now	NovoCure	$24.05	295.01%	→ $95	Reiterates	Buy → Buy	Get Alert
05/26/2023	EOLS	Buy Now	Evolus	$13.42	34.13%	$14 → $18	Maintains	Buy	Get Alert
05/26/2023	CORT	Buy Now	Corcept Therapeutics	$29.47	-11.76%	$28 → $26	Maintains	Hold	Get Alert
05/26/2023	ARQT	Buy Now	Arcutis Biotherapeutics	$9.23	333.37%	$45 → $40	Maintains	Buy	Get Alert
05/09/2023	ANIP	Buy Now	ANI Pharmaceuticals	$61.73	-15.76%	$50 → $52	Maintains	Buy	Get Alert
03/29/2023	AMRX	Buy Now	Amneal Pharmaceuticals	$6.82	-41.35%	$5 → $4	Maintains	Buy	Get Alert
03/29/2023	ARQT	Buy Now	Arcutis Biotherapeutics	$9.23	387.54%	$50 → $45	Maintains	Buy	Get Alert
11/08/2022	CORT	Buy Now	Corcept Therapeutics	$29.47	-4.98%	$30 → $28	Maintains	Hold	Get Alert
10/28/2022	NVCR	Buy Now	NovoCure	$24.05	324.12%	$105 → $102	Maintains	Buy	Get Alert
09/27/2022	BTMD	Buy Now	Biote	$5.20	92.31%	→ $10	Initiates	→ Buy	Get Alert
08/24/2022	AERI	Buy Now	Aerie Pharmaceuticals	—	—	—	Downgrade	Buy → Hold	Get Alert
08/01/2022	CORT	Buy Now	Corcept Therapeutics	$29.47	1.81%	→ $30	Downgrade	Buy → Hold	Get Alert
07/29/2022	NVCR	Buy Now	NovoCure	$24.05	336.59%	$118 → $105	Maintains	Buy	Get Alert
07/29/2022	BHC	Buy Now	Bausch Health Companies	$6.72	—	—	Downgrade	Buy → Hold	Get Alert
06/29/2022	XAIR	Buy Now	Beyond Air	$1.39	1338.85%	$16 → $20	Maintains	Buy	Get Alert
05/17/2022	CRXT	Buy Now	Clarus Therapeutics Hldgs	—	—	$7 → $3	Maintains	Buy	Get Alert
04/14/2022	ATRS	Buy Now	Antares Pharma	—	—	$7 → $5.6	Downgrade	Buy → Hold	Get Alert
01/28/2022	CORT	Buy Now	Corcept Therapeutics	$29.47	1.81%	→ $30	Initiates	→ Buy	Get Alert

Recent Analyst Stock Rating News

Evaluating ANI Pharmaceuticals: Insights From 5 Financial Analysts

Expert Outlook: ANI Pharmaceuticals Through The Eyes Of 4 Analysts

Why Corcept Therapeutics Stock Popped Today

Corcept Therapeutics Incorporated (NASDAQ: CORT) shares surged Thursday following a second-quarter earnings beat.

Golden Spike Developing Gregory River Copper-Gold Project In Low Political Risk Newfoundland, Canada

Golden Spike Resources (CNSX: GLDS) (OTCQB: GSPRF) (Frankfurt: L5Y) is a mineral exploration company developing resource projects in low-risk jurisdictions.